23 February 2021 - Antengene today announced that China's National Medical Products Administration has granted priority review to the new drug application for ATG-010 (selinexor, Xpovio), a first-in-class selective inhibitor of nuclear export (SINE) compound, for the treatment of patients with relapsed/refractory multiple myeloma.

Antengene has completed patient enrolment for the registrational clinical trial in relapsed/refractory multiple myeloma in mainland China and has submitted new drug applications for ATG-010 in five APAC markets including Australia, South Korea and Singapore over the past six months.

Read Antegene press release